Spectrum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SPPI Spectrum Pharmaceuticals Inc
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
FRST Primis Financial Corp
VII 7GC & Holdings Co Inc
PEBO Peoples Bancorp Inc
BIOAF Bioasis Technologies Inc
NRGOF Newrange Gold Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. The Company's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

Closing Price
$0.8198
Day's Change
0.0098 (1.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.83
Day's Low
0.7988
Volume
(Light)
Volume:
1,129,883

10-day average volume:
2,318,281
1,129,883

ConocoPhillips (COP) is Attracting Investor Attention: Here is What You Should Know

9:00 am ET November 24, 2022 (Zacks) Print

ConocoPhillips (COP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this energy company have returned +0.1%, compared to the Zacks S&P 500 composite's +7.5% change. During this period, the Zacks Oil and Gas - Integrated - United States industry, which ConocoPhillips falls in, has gained 2.8%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings Estimates

Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, ConocoPhillips is expected to post earnings of $3.44 per share, indicating a change of +51.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +3% over the last 30 days.

The consensus earnings estimate of $14.25 for the current fiscal year indicates a year-over-year change of +137.1%. This estimate has changed +1.7% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $13.40 indicates a change of -6% from what ConocoPhillips is expected to report a year ago. Over the past month, the estimate has changed +1.9%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, ConocoPhillips is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue Growth

While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For ConocoPhillips, the consensus sales estimate for the current quarter of $17.75 billion indicates a year-over-year change of +11.2%. For the current and next fiscal years, $77.25 billion and $66.02 billion estimates indicate +59.8% and -14.5% changes, respectively.

Last Reported Results and Surprise History

ConocoPhillips reported revenues of $21.61 billion in the last reported quarter, representing a year-over-year change of +86.1%. EPS of $3.60 for the same period compares with $1.77 a year ago.

Compared to the Zacks Consensus Estimate of $17.05 billion, the reported revenues represent a surprise of +26.76%. The EPS surprise was +5.57%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

Valuation

No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

ConocoPhillips is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Conclusion

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about ConocoPhillips. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
ConocoPhillips (COP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.